← Back to headlines
Lantheus Receives Complete Response Letter for LNTH-2501
Lantheus Holdings, Inc. has announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application for LNTH-2501.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
